San Francisco, March 22, 2021 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, today announced that it is participating at the BIO-Europe Spring.
Read MoreInterim Analysis of Recardio’s Phase II Clinical Trial published in European Heart Journal
San Francisco, December 17, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio’s Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.
Read MoreStudy Protocol of Phase 2 Trial of Recardio Published in the Trials Journal BioMed Central
San Francisco, September 14, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the study protocol for its Clinical Phase 2 Study. Entitled “Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”, the article can be accessed here: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04652-0
Read MoreInterim Analysis of Recardio’s Phase II Clinical Trial to be Presented at the 2020 Congress of the European Society of Cardiology
San Francisco, June 29, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio’s Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29th through September 1st.
Read MoreClinical Trial Outcomes of Recardio’s Dutogliptin Published in the British Journal of Pharmacology
San Francisco, May 15, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208
Read More- 1
- 2
- 3
- …
- 6
- Next Page »